Clinical trials: Adaptive Trial
Influenza
Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Anhui/1/2013 (H7N9) administered at 3 dose levels in adjuvanted (SE) rHA formulations…
- Trial name
- PSC26 (NCT02464163)
- Testing
- Panblok, rHA adjuvant
- Where
- 9 sites in United States
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
COVID-19
Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
The primary objective of this study is to assess the feasibility and acceptability of methods and procedures to be employed in a larger scale decentralized platform adaptive randomized clinical trial in patients with a history of…
- Trial name
- NCT05946551
- Testing
- Cetirizine, Famotidine
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Type 1 Diabetes
Adaptive Biobehavioral Control (ABC) in a Closed-Loop System
This study is intended to test a Web-based Information Tool (WIT) software providing additional information regarding time in range, GMI, hypo- and hyperglycemia risks, variability tracker, daily glycemic profiles, and potential…
- Trial name
- ABC-WIT (NCT05610111)
- Testing
- CLC + BAM, CLC + ABC
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Sue Brown
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
This randomized phase II trial studies how well carboplatin and combination chemotherapy with or without veliparib works in treating patients with stage IIB-IIIC breast cancer.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01818063
- Testing
- Paclitaxel, Carboplatin, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
COVID-19
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of PF-07304814 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780541
- Testing
- PF-07304814, Remdesivir
- Where
- 40 sites in United States, Denmark
- Volunteers
- 58 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Brain Cancer, Glioblastoma Multiforme
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase I Objectives: -To determine the maximum tolerated dose (MTD) of vorinostat + erlotinib versus vorinostat + erlotinib + temozolomide in adult patients with recurrent glioblastoma multiforme (GBM) and anaplastic gliomas.
- Trial name
- NCT01110876
- Testing
- Vorinostat, Erlotinib, Temozolomide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer, Oropharyngeal Cancer
A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer
The goal of this clinical research study is to use computed tomography (CT) scans to measure and guide your radiation therapy. Researchers want to learn if the CT scans can be used to adapt radiation therapy to the changes in…
- Trial name
- NCT00490282
- Testing
- Intensity Modulated Radiation Therapy, Adaptive Radiotherapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Physical Activity
Testing Adaptive Interventions to Improve Physical Activity for Sedentary Women
This study employs a Sequential Multiple Assignment Randomized Trial (SMART) and aims to determine the most effective adaptive intervention combining four efficacious treatments (enhanced physical activity monitor, motivational…
- Trial name
- NCT03558828
- Testing
- Step 1: PA Monitor, Step 1: PA Monitor + Text, Step 2: PA Monitor with Calls
- Where
- United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Cardiovascular Risk Factor
Random Assignment of Intervention Messages for Developing Personalized Decision Rules to Promote Physical Activity
Our goal is to develop personalized decision rules for selecting the frequency, timing, and content of messages to promote physical activity.
- Trial name
- RandomAIM (NCT03907683)
- Testing
- Short Message with Text and Optional Image
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Penn State University
Cardiac Arrest
Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial
Cardiac arrest is a sudden, unexpected loss of heart function. Therapeutic hypothermia, in which the body's temperature is lowered and maintained several degrees below normal for a period of time, has been used to successfully…
- Trial name
- THAPCA-IH (NCT00880087)
- Testing
- Therapeutic Hypothermia, Therapeutic Normothermia
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 329 people
- Sponsor
- University of Michigan
COVID-19
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
A multi-center adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis
- Trial name
- NCT04498273
- Testing
- Apixaban 2.5 MG, Apixaban 5MG, Aspirin
- Where
- 71 sites in United States
- Volunteers
- 657 people
- Sponsor
- Frank C Sciurba
SARS-CoV-2
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute…
- Trial name
- PROTECT-APT 1 (NCT05954286)
- Testing
- Upamostat
- Where
- 6 sites in United States, South Africa and 2 more
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Cocaine-Related Disorders
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
First, the investigators will determine whether Acceptance and Commitment Therapy in combination with Contingency Management increases initial treatment response rates.
- Trial name
- NCT02896712
- Testing
- Acceptance and Commitment Therapy (ACT), Drug Counseling (DC), Contingency Management (CM)
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- The University of Texas Health Science Center, Houston
COVID-19
Adaptive COVID-19 Treatment Trial (ACTT)
This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19.
- Trial name
- NCT04280705
- Testing
- Remdesivir
- Where
- 60 sites in United States, Denmark and 8 more
- Volunteers
- 1,062 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Nocturia
A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
The purpose of this trial was to investigate the efficacy, safety and tolerability of different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to nocturnal polyuria in…
- Trial name
- NCT03201419
- Testing
- FE 201836, Desmopressin
- Where
- 72 sites in United States, Belgium and 5 more
- Volunteers
- 302 people
- Sponsor
- Ferring Pharmaceuticals
Atopic Dermatitis, Atopic Hand Eczema
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
The purpose of this study is to test if treatment with tralokinumab is safe and efficacious in treating moderate-to-severe atopic hand eczema.
- Trial name
- ADHAND (NCT05958407)
- Testing
- Tralokinumab
- Where
- 69 sites in United States, Belgium and 8 more
- Volunteers
- 235 people
- Sponsor
- LEO Pharma
Alzheimer's Disease, Mild Cognitive Impairment
Nicotinamide as an Early Alzheimer's Disease Treatment
The purpose of this research study is to test whether nicotinamide, also known as vitamin B3 or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that accumulates in neurofibrillary tangles) in…
- Trial name
- NEAT (NCT03061474)
- Testing
- Nicotinamide
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of California, Irvine
Triple-negative Breast Cancer
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy
This is a randomized, open-label, adaptive, two arm, multicentre, Phase II trial comparing a neoadjuvant chemotherapy with PDL1-inhibition (Atezolizumab) and Atezolizumab two-week window to chemotherapy with PDL1-inhibition…
- Trial name
- neoMono (NCT04770272)
- Testing
- Atezolizumab 840 MG in 14 ML Injection, Atezolizumab 1200 MG in 20 ML Injection, Carboplatin
- Where
- Germany
- Volunteers
- 442 people
- Sponsor
- Palleos Healthcare GmbH
Upper Respiratory Tract Infections, Virus
Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19)
ELVIS COVID-19 is a pragmatic web-based Bayesian adaptive randomised controlled, parallel group trial of hypertonic saline nasal irrigation and gargling (HSNIG) compared to standard care in participants with clinically suspected…
- Conditions
- Upper Respiratory Tract Infections, Virus, COVID, Virus Shedding
- Trial name
- NCT04382131
- Testing
- NaCl Solution
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University of Edinburgh
Septic Shock
Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial
This is a double-blind, randomised, placebo-controlled, two-part adaptive clinical trial. The trial is designed to investigate the efficacy and safety of multiple dosing regimens of selepressin and to confirm the efficacy and…
- Trial name
- SEPSIS-ACT (NCT02508649)
- Testing
- selepressin
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 868 people
- Sponsor
- Ferring Pharmaceuticals